Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration

Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer THOUSAND OAKS, Calif., Nov. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab). ABP 215 is the most advanced of the four oncology biosimilar medicines that Amgen and Allergan are collaborating on. The companies believe this submission is the first bevacizumab biosimilar application submitted to the FDA. "ABP 215 is one of four oncology biosimilars in our pipeline, and today's BLA submission is an impo...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news